UBS Group’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

UBS Group’s Portfolio SXTP Stock Details SXTP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$18K	Sell	13,526 -66	-0.5%	-$81	﹤0.01%	8585
2026 Q2	$23.9K	Sell	13,592 -17,818	-57%	-$28.7K	﹤0.01%	8055
2026 Q1	$55K	Buy	31,410 +31,041	+8,412%	+$88.2K	﹤0.01%	7313
2025 Q4	$750	Hold	369	–	–	﹤0.01%	9826
2025 Q3	$2.18K	Buy	369 +365	+9,125%	+$2.22K	﹤0.01%	9208
2025 Q2	$33	Sell	4 -4,043	-100%	-$40.5K	﹤0.01%	10085
2025 Q1	$29.8K	Buy	4,047 +3,027	+297%	+$37.2K	﹤0.01%	7950
2024 Q4	$26.3K	Buy	1,020 +854	+514%	+$18.8K	﹤0.01%	7706
2024 Q3	$4.14K	Buy	166 +22	+15%	+$813	﹤0.01%	8179
2024 Q2	$8.72K	Buy	+144	New	+$9.14K	﹤0.01%	7784

Other funds holding SXTP

Kathmere Capital Management Wayne, Pennsylvania $2.07B AUM 20.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

UBS Group's SXTP Position: Q3 2026 in Review

UBS Group reduced its 60 Degrees Pharmaceuticals (SXTP) stake by 0.49% in Q3 2026, selling an estimated $81 and leaving 13,526 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #8585.

UBS Group first reported a position in SXTP in Q2 2024 and has held it in 10 quarters since. The position peaked at $55K in Q1 2026. 5 funds tracked by Wall St. Rank hold SXTP as of Q3 2026.

UBS Group held 13,526 shares of 60 Degrees Pharmaceuticals worth $18K as of Q3 2026.
UBS Group sold 66 60 Degrees Pharmaceuticals shares in Q3 2026, an estimated $81.
60 Degrees Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8585 holding.
UBS Group first reported a position in 60 Degrees Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
UBS Group's 60 Degrees Pharmaceuticals position peaked at $55K in Q1 2026.
5 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.